Table: Daito -9-MTH group results
Apr 12 (Reuters)-
Daito Pharamaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Feb 29, 2016 Feb 28, 2015 May 31, 2016
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 27.01 24.65 37.00
(+9.6 pct) (+11.6 pct) (+8.6 pct)
Operating 2.75 2.39 3.55
(+14.8 pct) (+15.3 pct) (+0.9 pct)
Recurring 2.86 2.36 3.50
(+21.0 pct) (+14.4 pct) (+1.4 pct)
Net 1.91 1.52 2.30
(+25.9 pct) (+21.5 pct) (+2.4 pct)
EPS 152.74 yen 125.02 yen 183.78 yen
Ann Div 30.00 yen 30.00 yen
-Q2 div 15.00 yen 15.00 yen
-Q4 div 15.00 yen 15.00 yen
NOTE - Daito Pharamaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4577.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Daito Pharmaceutical
See all newsTo Buy Back Up To 4.4% Of Own Shares Worth 2 Billion Yen
Table: Daito Pharmaceutical -Q1 group results
Execution Of JV And Share Transfer Agreement For Transfer Of Kyorin Pharmaceutical's Generic Drug Business To JV By Daito, Meiji Seika Pharma And Dbj
Table: Daito -2025/26 parent results
Table: Daito -2025/26 group results